STERIS plc — fact timeline

STERIS plc reported the twelve months ended March 31, 2026 results: revenue $5.9 billion, net income $782.3 million or $7.93 per diluted share. Guidance raised.

“currency organic revenue growth from continuing operations grew 5% in the fourth quarter. Revenue from continuing operations for the full year fiscal 2026 increased 9% to $5.9 billion compared with $5.5 billion in fiscal 2025. Constant currency organic revenue growth from continuing operations grew 7% for fiscal 2026. “Fiscal 2026 was another record year,””

STERIS plc reported the three months ended March 31, 2026 results: revenue $1.6 billion, net income $220.3 million or $2.24 per diluted share.

“Total revenue from continuing operations for the fourth quarter of fiscal 2026 increased 7% to $1.6 billion compared with $1.5 billion in the fourth quarter of fiscal 2025.”

Pierre Boulud was appointed as Director at STERIS plc.

“On May 5, 2026, the Board of the Company increased its size from nine to ten members and appointed Pierre Boulud to serve as a director effective as of that date.”

Richard C. Breeden departed as Director at STERIS plc.

“On May 1, 2026, Richard C. Breeden notified STERIS plc (the “Company”) that he will not stand for reelection to the Board of Directors (the “Board”) at the Company’s 2026 Annual General Meeting of Shareholders.”

STERIS plc reported fiscal 2024 full year ended March 31, 2024 results: revenue $5.5 billion, net income $3.81 per diluted share, EPS $3.81 per diluted share.

“Total revenue for fiscal 2024 increased 12% to $5.5 billion compared with $5.0 billion in fiscal 2023.”

STERIS plc reported fiscal 2024 fourth quarter ended March 31, 2024 results: revenue $1.5 billion, net income ($0.01) per diluted share, EPS ($0.01) per diluted share.

“Total revenue for the fourth quarter of fiscal 2024 increased 10% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2023.”

STERIS plc announced a restructuring with charges of approximately $100 million affecting Healthcare surgical business in Europe.

“this plan to potentially impacted employees on May 7, 2024 and the restructuring is expected to be substantially completed by the end of fiscal 2025. The approximately $100 million of anticipated restructuring charges includes approximately $44.4 million recorded in the fiscal 2024 fourth quarter with the balance expected to be recorded in fiscal 2025. Of”

STERIS plc entered into Equity Purchase Agreement with HuFriedy Group Holding LLC valued at $787.5 million in cash, subject to customary adjustments, and up to $12.5 million in contingent paym (effective 2024-04-10).

“On April 10, 2024, STERIS Corporation (“Seller”), a wholly owned subsidiary of STERIS plc (“STERIS”), and certain affiliates, entered into an Equity Purchase Agreement (the “Purchase Agreement”) with HuFriedy Group Holding LLC (the “Purchaser”), an affiliate of Peak Rock Capital LLC.”

STERIS plc reported fiscal 2024 third quarter ended December 31, 2023 results: revenue $1.40 billion, EPS $1.42.

“Revenue as reported for the quarter increased 15% to $1.40 billion compared with $1.22 billion in the third quarter of fiscal 2023.”

STERIS plc reported fiscal 2024 second quarter ended September 30, 2023 results: revenue $1.34 billion, EPS $1.16 per diluted share. Guidance reaffirmed.

“STERIS Announces Financial Results for Fiscal 2024 Second Quarter • Second quarter revenue growth of 12% as reported and 8% constant currency organic • As reported diluted earnings per share increased to $1.16; adjusted earnings increased to $2.03 • Fiscal 2024 outlook maintained DUBLIN, IRELAND - (November 7, 2023) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024 second quarter ended September 30, 2023. Revenue as reported for the quarter increased 12% to $1.34 billion compared with $1.20 billion in the second quarter of fiscal 2023.”

STERIS plc shareholders approved Advisory vote on the frequency of say-on-pay votes at the 2023-07-27 meeting.

“the Company’s shareholders voted in favor of holding say-on-pay votes every year.”

STERIS plc reported fiscal 2024 first quarter ended June 30, 2023 results: revenue $1.28 billion, EPS $1.25; adjusted earnings increased to $2.00.

“STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024 first quarter ended June 30, 2023. Revenue as reported for the quarter increased 11% to $1.28 billion compared with $1.16 billion in the first quarter of fiscal 2023. Constant currency organic revenue (see”

STERIS plc shareholders approved Renewal of Board's authority to opt-out of statutory pre-emption rights under Irish law regarding issuance of shares for cash at the 2023-07-27 meeting.

“8. The shareholders approved the proposal to approve the renewal of the Board’s authority to opt-out of statutory pre-emption rights under Irish law regarding the issuance of shares for cash, by the following votes: Votes for 85,582,812 Votes against 5,955,437 Abstentions 179,601”

STERIS plc shareholders approved Renewal of Board's authority to issue authorized but unissued shares under Irish law at the 2023-07-27 meeting.

“7. The shareholders approved the proposal to the renewal of the Board’s authority to issue authorized but unissued shares under Irish law, by the following votes: Votes for 89,904,671 Votes against 1,766,723 Abstentions 46,456”

STERIS plc shareholders approved Advisory vote on frequency of say-on-pay votes at the 2023-07-27 meeting.

“6. The shareholders approved “one-year” for the proposal to approve, on a non-binding advisory basis whether the non-binding advisory vote on named executive officer compensation should be held every one, two or three years, by the following votes: One Year 87,154,402 Two Years 46,103 Three Years 923,796 Abstentions 42,734 Broker non-votes 3,550,815”

STERIS plc shareholders approved Advisory vote on compensation of named executive officers at the 2023-07-27 meeting.

“5. The shareholders approved the proposal to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 7, 2023, by the following votes: Votes for 81,238,272 Votes against 6,841,234 Abstentions 87,529 Broker non-votes 3,550,815”

STERIS plc shareholders approved Authorization to determine remuneration of Ernst & Young Chartered Accountants as statutory auditor at the 2023-07-27 meeting.

“4. The shareholders approved the proposal to authorize the Board of the Company or the Audit Committee of the Board to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law by the following votes: Votes for 90,452,843 Votes against 1,215,360 Abstentions 49,647”

STERIS plc shareholders approved Appointment of Ernst & Young Chartered Accountants as statutory auditor under Irish law at the 2023-07-27 meeting.

“3. The shareholders approved the proposal to appoint Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law to hold office until the conclusion of the Company’s next Annual General Meeting by the following votes: Votes for 83,051,183 Votes against 8,608,501 Abstentions 58,166”

STERIS plc shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending March 31, 2024 at the 2023-07-27 meeting.

“2. The shareholders approved the proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2024 by the following votes: Votes for 83,026,435 Votes against 8,633,905 Abstentions 57,510”

STERIS plc shareholders approved Election of directors for a one-year term at the 2023-07-27 meeting.

“1. The shareholders elected the nominees named below to the board of directors of the Company (the “Board”), each for a one-year term, and the results of the vote were as follows: Nominee Votes for Votes against Abstentions Broker non-votes Esther M. Alegria 87,930,589 166,648 69,798 3,550,815 Richard C. Breeden 83,412,606 4,674,581 79,848 3,550,815 Daniel A. Carestio 86,828,206 1,301,677 37,152 3,550,815 Cynthia L. Feldmann 78,692,106 5,944,870 3,530,059 3,550,815 Christopher S. Holland 87,150,387 932,962 83,686 3,550,815 Dr. Jacqueline B. Kosecoff 79,498,778 8,597,293 70,964 3,550,815 Paul E. Martin 86,306,636 1,785,736 74,663 3,550,815 Dr. Nirav R. Shah 87,034,737 1,007,908 124,390 3,550,815 Dr. Mohsen M. Sohi 83,787,674 4,300,162 79,199 3,550,815 Dr. Richard M. Steeves 87,059,127 1,031,717 76,191 3,550,815”

STERIS plc entered into Asset Purchase Agreement with Becton, Dickinson and Company valued at $540 million (effective 2023-06-15).

“On June 15, 2023, STERIS plc (“STERIS”) and STERIS Corporation (“Purchaser”), a wholly owned subsidiary of STERIS, entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Becton, Dickinson and Company (the “Seller”).”

STERIS plc reported fiscal 2023 fourth quarter and full year ended March 31, 2023 results: revenue $1.38 billion, EPS $1.88. Guidance initiated.

“or the “Company”) today announced financial results for its fiscal 2023 fourth quarter and full year ended March 31, 2023. Revenue as reported for the quarter increased 14% to $1.38 billion compared with $1.21 billion in the fourth quarter of fiscal 2022. Constant currency organic revenue (see”

Esther Alegria was elected as Director at STERIS plc.

“The Board of Directors (the “Board”) of STERIS plc (the “Company”) increased its size from nine to ten members on May 3, 2023, and elected Dr. Esther Alegria to serve as a director effective as of that date.”

STERIS plc reported fiscal 2023 third quarter ended December 31, 2022 results: revenue $1.22 billion, EPS $1.24.

“STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 third quarter ended December 31, 2022. Revenue as reported for the quarter increased 1% to $1.22 billion compared with $1.21 billion in the third quarter of fiscal 2022. Constant currency organic revenue (see”

STERIS plc reported fiscal 2023 second quarter ended September 30, 2022 results: revenue $1.2 billion, EPS as reported loss per share of ($3.15); adjusted EPS of $1.99.

“STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 second quarter ended September 30, 2022. Revenue as reported for the quarter was flat at $1.2 billion compared with $1.2 billion in the second quarter of fiscal 2022. Constant currency organic revenue (see”